Olaparib

Generic Name
Olaparib
Brand Names
Lynparza
Drug Type
Small Molecule
Chemical Formula
C24H23FN4O3
CAS Number
763113-22-0
Unique Ingredient Identifier
WOH1JD9AR8
Background

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...

Indication

Ovarian cancer

Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions
Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

First Posted Date
2015-09-28
Last Posted Date
2019-02-20
Lead Sponsor
AstraZeneca
Target Recruit Count
15
Registration Number
NCT02561832
Locations
🇪🇸

Research Site, Zaragoza, Spain

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

First Posted Date
2015-09-11
Last Posted Date
2024-12-12
Lead Sponsor
AstraZeneca
Target Recruit Count
117
Registration Number
NCT02546661
Locations
🇬🇧

Research Site, Southampton, United Kingdom

Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

First Posted Date
2015-08-27
Last Posted Date
2021-02-26
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
18
Registration Number
NCT02533765
Locations
🇮🇹

Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale", Napoli, Italy

🇮🇹

U.O Oncologia Medica, IRST IRCCS, Meldola, FC, Italy

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

First Posted Date
2015-07-30
Last Posted Date
2019-11-07
Lead Sponsor
AstraZeneca
Target Recruit Count
128
Registration Number
NCT02511795
Locations
🇨🇦

Research Site, Toronto, Ontario, Canada

Efficacy and Safety of PARPi to Treat Pancreatic Cancer

Phase 2
Completed
Conditions
Pancreatic Cancer
Interventions
Drug: OLAPARIB
First Posted Date
2015-07-29
Last Posted Date
2023-04-19
Lead Sponsor
Sheba Medical Center
Target Recruit Count
24
Registration Number
NCT02511223
Locations
🇮🇱

Sheba Medical Centre, Ramat Gan, Israel

Preoperative Olaparib Endometrial Carcinoma Study (POLEN)

Completed
Conditions
Endometrial Carcinoma
Interventions
Drug: Olaparib
First Posted Date
2015-07-23
Last Posted Date
2020-11-30
Lead Sponsor
MedSIR
Target Recruit Count
36
Registration Number
NCT02506816
Locations
🇪🇸

MedSIR investigative site, Vigo, Spain

🇪🇸

MedSIR, Madrid, Spain

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

First Posted Date
2015-07-20
Last Posted Date
2024-07-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
587
Registration Number
NCT02502266
Locations
🇺🇸

West Penn Hospital, Pittsburgh, Pennsylvania, United States

🇺🇸

Pacific Gynecology Specialists, Seattle, Washington, United States

🇺🇸

Women's Cancer Center of Seattle, Seattle, Washington, United States

and more 397 locations

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

First Posted Date
2015-07-15
Last Posted Date
2024-08-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
122
Registration Number
NCT02498613
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States

🇺🇸

Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States

and more 13 locations

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

First Posted Date
2015-07-02
Last Posted Date
2024-01-17
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
71
Registration Number
NCT02489006
Locations
🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

🇨🇦

Centre hospitalier de l'Université de Montréal (CHUM, Montréal, Quebec, Canada

🇨🇦

Jewish General Hospital, Montréal, Quebec, Canada

and more 6 locations

Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

Phase 1
Terminated
Conditions
Primary Peritoneal Carcinoma
Interventions
Drug: Tremelimumab
Drug: Olaparib
First Posted Date
2015-06-30
Last Posted Date
2021-04-12
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
24
Registration Number
NCT02485990
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy